Christopher Southan

List of Publications by Year
in descending order

126	16,460	31976 53	19749 117
papers	citations	h-index	g-index

151	151	151	19406
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The IUPHAR/BPS guide to PHARMACOLOGY in 2022: curating pharmacology for COVID-19, malaria and antibacterials. Nucleic Acids Research, 2022, 50, D1282-D1294.	14.5	99
2	Will the chemical probes please stand up?. RSC Medicinal Chemistry, 2021, 12, 1428-1441.	3.9	7
3	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Enzymes. British Journal of Pharmacology, 2021, 178, S313-S411.	5.4	320
4	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Catalytic receptors. British Journal of Pharmacology, 2021, 178, S264-S312.	5.4	148
5	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Ion channels. British Journal of Pharmacology, 2021, 178, S157-S245.	5.4	187
6	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Introduction and Other Protein Targets. British Journal of Pharmacology, 2021, 178, S1-S26.	5.4	183
7	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Nuclear hormone receptors. British Journal of Pharmacology, 2021, 178, S246-S263.	5.4	100
8	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Transporters. British Journal of Pharmacology, 2021, 178, S412-S513.	5.4	114
9	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G proteinâ€coupled receptors. British Journal of Pharmacology, 2021, 178, S27-S156.	5.4	337
10	The IUPHAR/BPS Guide to PHARMACOLOGY in 2020: extending immunopharmacology content and introducing the IUPHAR/MMV Guide to MALARIA PHARMACOLOGY. Nucleic Acids Research, 2020, 48, D1006-D1021.	14.5	131
11	A rational roadmap for SARSâ€CoVâ€2/COVIDâ€19 pharmacotherapeutic research and development: IUPHAR Review 29. British Journal of Pharmacology, 2020, 177, 4942-4966.	5.4	61
12	The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology. Immunology, 2020, 160, 10-23.	4.4	7
13	Opening up connectivity between documents, structures and bioactivity. Beilstein Journal of Organic Chemistry, 2020, 16, 596-606.	2.2	2
14	DÃ©jÃ vu: Stimulating open drug discovery for SARS-CoV-2. Drug Discovery Today, 2020, 25, 928-941.	6.4	81
15	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G proteinâ€coupled receptors. British Journal of Pharmacology, 2019, 176, S21-S141.	5.4	519
16	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology, 2019, 176, S142-S228.	5.4	242
17	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Nuclear hormone receptors. British Journal of Pharmacology, 2019, 176, S229-S246.	5.4	127
18	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors. British Journal of Pharmacology, 2019, 176, S247-S296.	5.4	156

#	Article	IF	Citations
19	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes. British Journal of Pharmacology, 2019, 176, S297-S396.	5.4	423
20	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology, 2019, 176, S397-S493.	5.4	166
21	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets. British Journal of Pharmacology, 2019, 176, S1-S20.	5.4	295
22	Inverse pharmacology: Approaches and tools for introducing druggability into engineered proteins. Biotechnology Advances, 2019, 37, 107439.	11.7	2
23	Hydrolases (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	0
24	Hydrolases (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	1
25	Caveat Usor: Assessing Differences between Major Chemistry Databases. ChemMedChem, 2018, 13, 470-481.	3.2	12
26	Accessing Expertâ€Curated Pharmacological Data in the IUPHAR/BPS Guide to PHARMACOLOGY. Current Protocols in Bioinformatics, 2018, 61, 1.34.1-1.34.46.	25.8	13
27	SynPharm: A Guide to PHARMACOLOGY Database Tool for Designing Drug Control into Engineered Proteins. ACS Omega, 2018, 3, 7993-8002.	3.5	4
28	Challenges of Connecting Chemistry to Pharmacology: Perspectives from Curating the IUPHAR/BPS Guide to PHARMACOLOGY. ACS Omega, 2018, 3, 8408-8420.	3.5	3
29	The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Research, 2018, 46, D1091-D1106.	14.5	1,584
30	THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Nuclear hormone receptors. British Journal of Pharmacology, 2017, 174, S208-S224.	5.4	131
31	THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Voltageâ€gated ion channels. British Journal of Pharmacology, 2017, 174, S160-S194.	5.4	178
32	THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G proteinâ€coupled receptors. British Journal of Pharmacology, 2017, 174, S17-S129.	5.4	557
33	THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Ligandâ€gated ion channels. British Journal of Pharmacology, 2017, 174, S130-S159.	5.4	144
34	THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Other ion channels. British Journal of Pharmacology, 2017, 174, S195-S207.	5.4	41
35	THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview. British Journal of Pharmacology, 2017, 174, S1-S16.	5.4	269
36	Is systems pharmacology ready to impact upon therapy development? A study on the cholesterol biosynthesis pathway. British Journal of Pharmacology, 2017, 174, 4362-4382.	5.4	17

#	Article	IF	Citations
37	THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes. British Journal of Pharmacology, 2017, 174, S272-S359.	5.4	597
38	THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Transporters. British Journal of Pharmacology, 2017, 174, S360-S446.	5.4	193
39	THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Catalytic receptors. British Journal of Pharmacology, 2017, 174, S225-S271.	5.4	177
40	Last rolls of the yoyo: Assessing the human canonical protein count. F1000Research, 2017, 6, 448.	1.6	11
41	Illustrating and homology modeling the proteins of the Zika virus. F1000Research, 2016, 5, 275.	1.6	37
42	Retrieving GPCR data from public databases. Current Opinion in Pharmacology, 2016, 30, 38-43.	3.5	4
43	Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos Arylpyrroles. ACS Central Science, 2016, 2, 687-701.	11.3	68
44	Endothelin. Pharmacological Reviews, 2016, 68, 357-418.	16.0	574
45	The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Research, 2016, 44, D1054-D1068.	14.5	1,075
46	Illustrating and homology modeling the proteins of the Zika virus. F1000Research, 2016, 5, 275.	1.6	25
47	The Concise Guide to PHARMACOLOGY 2015/16: Overview. British Journal of Pharmacology, 2015, 172, 5729-5743.	5.4	220
48	The Concise Guide to PHARMACOLOGY 2015/16: Ligandâ€gated ion channels. British Journal of Pharmacology, 2015, 172, 5870-5903.	5.4	133
49	The Concise Guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors. British Journal of Pharmacology, 2015, 172, 5956-5978.	5.4	119
50	The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. British Journal of Pharmacology, 2015, 172, 6024-6109.	5.4	521
51	The Concise Guide to PHARMACOLOGY 2015/16: Transporters. British Journal of Pharmacology, 2015, 172, 6110-6202.	5.4	190
52	The Concise Guide to PHARMACOLOGY 2015/16: G proteinâ€coupled receptors. British Journal of Pharmacology, 2015, 172, 5744-5869.	5.4	507
53	The Concise Guide to PHARMACOLOGY 2015/16: Voltageâ€gated ion channels. British Journal of Pharmacology, 2015, 172, 5904-5941.	5.4	176
54	The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors. British Journal of Pharmacology, 2015, 172, 5979-6023.	5.4	158

#	Article	IF	Citations
55	The Concise Guide to PHARMACOLOGY 2015/16: Other ion channels. British Journal of Pharmacology, 2015, 172, 5942-5955.	5.4	40
56	Expanding opportunities for mining bioactive chemistry from patents. Drug Discovery Today: Technologies, 2015, 14, 3-9.	4.0	18
57	Parallel Worlds of Public and Commercial Bioactive Chemistry Data. Journal of Medicinal Chemistry, 2015, 58, 2068-2076.	6.4	28
58	Finding small molecules for the â€˜next Ebolaâ€™. F1000Research, 2015, 4, 58.	1.6	17
59	Finding small molecules for the â€˜next Ebolaâ€™. F1000Research, 2015, 4, 58.	1.6	14
60	The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Research, 2014, 42, D1098-D1106.	14.5	826
61	Extracting and connecting chemical structures from text sources using chemicalize.org. Journal of Cheminformatics, 2013, 5, 20.	6.1	38
62	InChI in the wild: an assessment of InChIKey searching in Google. Journal of Cheminformatics, 2013, 5, 10.	6.1	36
63	Challenges and recommendations for obtaining chemical structures of industry-provided repurposing candidates. Drug Discovery Today, 2013, 18, 58-70.	6.4	24
64	BACE2 as a new diabetes target: a patent review (2010 â€“ 2012). Expert Opinion on Therapeutic Patents, 2013, 23, 649-663.	5.0	19
65	Comparing the Chemical Structure and Protein Content of ChEMBL, DrugBank, Human Metabolome Database and the Therapeutic Target Database. Molecular Informatics, 2013, 32, 881-897.	2.5	28
66	A tale of two drug targets: the evolutionary history of BACE1 and BACE2. Frontiers in Genetics, 2013, 4, 293.	2.3	17
67	Tracking 20 Years of Compound-to-Target Output from Literature and Patents. PLoS ONE, 2013, 8, e77142.	2.5	17
68	Shouldn't enantiomeric purity be included in the 'minimum information about a bioactive entity? Response from the MIABE group. Nature Reviews Drug Discovery, 2012, 11, 730-730.	46.4	0
69	SARConnect: A Tool to Interrogate the Connectivity Between Proteins, Chemical Structures and Activity Data. Molecular Informatics, 2012, 31, 555-568.	2.5	9
70	Mapping Between Databases of Compounds and Protein Targets. Methods in Molecular Biology, 2012, 910, 145-164.	0.9	16
71	Minimum information about a bioactive entity (MIABE). Nature Reviews Drug Discovery, 2011, 10, 661-669.	46.4	80
72	Making every SAR point count: the development of Chemistry Connect for the large-scale integration of structure and bioactivity data. Drug Discovery Today, 2011, 16, 1019-1030.	6.4	69

#	Article	IF	Citations
73	Analysis of in vitrobioactivity data extracted from drug discovery literature and patents: Ranking 1654 human protein targets by assayed compounds and molecular scaffolds. Journal of Cheminformatics, 2011, 3, 14.	6.1	31
74	Towards BioDBcore: a community-defined information specification for biological databases. Database: the Journal of Biological Databases and Curation, 2011, 2011, baq027-baq027.	3.0	30
75	Towards BioDBcore: a community-defined information specification for biological databases. Nucleic Acids Research, 2011, 39, D7-D10.	14.5	32
76	The Cinderella of Biological Data Integration: Addressing Some of the Challenges of Entity and Relationship Mining from Patent Sources. Lecture Notes in Computer Science, 2010, , 106-121.	1.3	1
77	Quantitative assessment of the expanding complementarity between public and commercial databases of bioactive compounds. Journal of Cheminformatics, 2009, 1, 10.	6.1	55
78	Thrombin-induced fibrinopeptide release from a fibrinogen variant (fibrinogen Sydney I) with an AÎ± Arg-16 â† His substitution. FEBS Journal, 2008, 147, 593-600.	0.2	24
79	Complementarity Between Public and Commercial Databases: New Opportunities in Medicinal Chemistry Informatics. Current Topics in Medicinal Chemistry, 2007, 7, 1502-1508.	2.1	31
80	Exploiting new genome data and Internet resources for the phylogenetic analysis of proteases, substrates and inhibitors. Biochemical Society Transactions, 2007, 35, 599-603.	3.4	2
81	Splice variants: A homology modeling approach. Proteins: Structure, Function and Bioinformatics, 2004, 54, 596-608.	2.6	24
82	Has the yo-yo stopped? An assessment of human protein-coding gene number. Proteomics, 2004, 4, 1712-1726.	2.2	85
83	The HtrA Family of Proteases. Molecular Cell, 2002, 10, 443-455.	9.7	597
84	The characterisation of novel secreted Ly-6 proteins from rat urine by the combined use of two-dimensional gel electrophoresis, microbore high performance liquid chromatography and expressed sequence tag data. Proteomics, 2002, 2, 187-196.	2.2	22
85	Proteomic approaches to central nervous system disorders. Current Opinion in Molecular Therapeutics, 2002, 4, 251-8.	2.8	5
86	Identification, Genomic Organization, and mRNA Expression of LACTB, Encoding a Serine Î²-Lactamase-like Protein with an Amino-terminal Transmembrane Domain. Genomics, 2001, 78, 12-14.	2.9	38
87	A genomic perspective on human proteases. FEBS Letters, 2001, 498, 214-218.	2.8	41
88	A genomic perspective on human proteases as drug targets. Drug Discovery Today, 2001, 6, 681-688.	6.4	87
89	BIOINFORMATIC ANALYSIS OF mRNA HETEROGENAITY IN THE PUTATIVE ALZHEIMERS BETA-SECRETASE, ASP2. Biochemical Society Transactions, 2000, 28, A84-A84.	3.4	1
90	The Impact of Genomics on Drug Discovery. Progress in Medicinal Chemistry, 2000, 37, 1-43.	10.4	19

#	Article	IF	Citations
91	InterPro (The Integrated Resource of Protein Domains and Functional Sites). Yeast, 2000, 1, 327-334.	1.7	10
92	Assessing the protease and protease inhibitor content of the human genome. Journal of Peptide Science, 2000, 6, 453-458.	1.4	24
93	Characterization of human HtrA2, a novel serine protease involved in the mammalian cellular stress response. FEBS Journal, 2000, 267, 5699-5710.	0.2	227
94	Sequencing, tissue distribution and chromosomal assignment of a novel ubiquitin-specific protease USP23. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2000, 1490, 184-188.	2.4	5
95	ASP1 (BACE2) Cleaves the Amyloid Precursor Protein at the Î²-Secretase Site. Molecular and Cellular Neurosciences, 2000, 16, 609-619.	2.2	156
96	Disposable Microbore High-Pressure Liquid Chromatography Columns for Protein and Peptide Separations. Analytical Biochemistry, 1999, 271, 152-158.	2.4	8
97	Identification of a Novel Aspartic Protease (Asp 2) as Î²-Secretase. Molecular and Cellular Neurosciences, 1999, 14, 419-427.	2.2	1,056
98	Expression, purification and characterization of a human serine-dependent phospholipase A2 with high specificity for oxidized phospholipids and platelet activating factor. Biochemical Journal, 1998, 330, 1309-1315.	3.7	34
99	Purification, Properties, Sequencing, and Cloning of a Lipoprotein-Associated, Serine-Dependent Phospholipase Involved in the Oxidative Modification of Low-Density Lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 591-599.	2.4	143
100	Synergistic scale-down of three protein micropreparation techniques. The Protein Journal, 1992, 11, 349-349.	1.1	0
101	Analytical and micropreparative capillary electrophoresis of the peptides from calcitonin. Analytical Biochemistry, 1991, 198, 36-42.	2.4	39
102	Separation by capillary electrophoresis followed by dynamic elution. Analytical Biochemistry, 1991, 196, 178-182.	2.4	13
103	Inactivation of dopamine Î²-hydroxylase by p-cresol: Evidence for a second, minor site of covalent modification at tyrosine 357. BBA - Proteins and Proteomics, 1990, 1037, 256-258.	2.1	17
104	Purification to apparent homogeneity and partial amino acid sequence of rat liverO6-alkylguanine-DNA-alkyltransferase. Nucleic Acids Research, 1990, 18, 13-16.	14.5	40
105	Bovine dopamine .beta.-hydroxylase, primary structure determined by cDNA cloning and amino acid sequencing. Biochemistry, 1990, 29, 6466-6474.	2.5	22
106	Rat ATP citrate-lyase. Molecular cloning and sequence analysis of a full-length cDNA and mRNA abundance as a function of diet, organ, and age. Journal of Biological Chemistry, 1990, 265, 1430-5.	3.4	96
107	Sequence similarity between dopamine Î²-hydroxylase and peptide Î±-amidating enzyme: Evidence for a conserved catalytic domain. FEBS Letters, 1989, 255, 116-120.	2.8	69
108	Inactivation of dopamine .beta.-hydroxylase by .beta.-ethynyltyramine: kinetic characterization and covalent modification of an active site peptide. Biochemistry, 1989, 28, 3833-3842.	2.5	28

#	Article	IF	Citations
109	THE USE OF GLASS CAPILLARY TUBES AS DISPOSABLE MICROBORE COLUMNS FOR RP-HPLC OF PROTEINS AND PEPTIDES. , 1989, , 392-398.		3
110	Inactivation of dopamine .beta.-hydroxylase by p-cresol: isolation and characterization of covalently modified active site peptides. Biochemistry, 1988, 27, 9093-9101.	2.5	67
111	The nitroreductase enzyme in walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-YL)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochemical Pharmacology, 1988, 37, 4671-4677.	4.4	148
112	Amino acid sequence of Î²-galactoside-binding bovine heart lectin. FEBS Letters, 1987, 214, 301-304.	2.8	32
113	Use of sep-pak cartridges for on-line preparative high-performance liquid chromatography. Journal of Chromatography A, 1987, 397, 399-404.	3.7	6
114	Direct analysis of plasma fibrinogenâ€derived fibrinopeptides by highâ€performance liquid chromatography: investigation of nine congenital fibrinogen abnormalities. British Journal of Haematology, 1987, 65, 469-473.	2.5	6
115	Direct analysis of plasma fibrinogen-derived fibrinopeptides by high-performance liquid chromatography. Thrombosis Research, 1986, 43, 195-204.	1.7	9
116	Characterization of peptides cleaved by plasmin from the C-terminal polymerization domain of human fibrinogen. Journal of Biological Chemistry, 1985, 260, 13095-101.	3.4	26
117	Genetically abnormal fibrinogens--strategies for structure elucidation, including fibrinopeptide analysis. Current Problems in Clinical Biochemistry, 1984, 14, 273-320.	0.1	5
118	Fibrinogen Manchester: identification of an abnormal fibrinopeptide A with a C-terminal arginineâ†'histidine substitution. British Journal of Haematology, 1983, 54, 143-151.	2.5	21
119	Delayed release of an abnormal fibrinopeptide A from fibrinogen Manchester: effect of the AÎ± 16 Arg â†' His substitution upon fibrin monomer polymerization and the immunological crossreactivity of the peptide. British Journal of Haematology, 1983, 53, 587-597.	2.5	20
120	COVALENT STRUCTURE OF FIBRINOGEN. Annals of the New York Academy of Sciences, 1983, 408, 28-43.	3.8	248
121	Genetically abnormal fibrinogens - some current characterisation strategies. , 1983, , 125-144.		8
122	Internet Resources for the Geneticist. , 0, , 21-37.		0
123	Finding, Delineating and Analysing Genes. , 0, , 71-91.		1
124	Finding, Delineating and Analysing Genes. , 0, , 85-104.		0
125	A Bioinformatics Perspective on Genetics in Drug Discovery and Development. , 0, , 495-528.		1
126	SCINDR - The SCience INtroDuction Robot that will Connect Open Scientists. Research Ideas and Outcomes, 0, 2, e9995.	1.0	1